DDW Exclusive Content

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick, about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. At the beginning of 2023, proteomics company Nautilus Biotechnology announced a partnership with the Translational Genomics Research Institute (TGen), to study […]

This paid-for advertorial by BC Platforms appeared in DDW Volume 24 – Issue 2, Spring 2023 BC Platforms’ Global Data Partner Network provides patient-level, longitudinal, and geographically diverse real-world data and real-world evidence for use as external control arms in randomised human clinical trials, which can accelerate medicinal product regulatory filings and market access. In […]

This paid-for advertorial by SPT Labtech appeared in DDW Volume 24 – Issue 2, Spring 2023 Paul Lomax, Head of Genomics at SPT Labtech, explains how exciting new technological developments have opened up opportunities for widespread innovation. mosquito® and dragonfly®: Minaturising next-generation sequencing (NGS) SPT Labtech is known across the industry for its highly successful […]

This paid-for advertorial by IRBM appeared in DDW Volume 24 – Issue 2, Spring 2023 The landscape for treating rare cancers is changing with advances in molecular genetics, novel drug modalities and patient-derived models. Dr Alessandro Carugo, IRBM, explains how building unique drug discovery strategies and expert alliances is reshaping the rare cancer drug ecosystem. Why […]

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Even with rigorous optimisation and validation, we face a 90% failure rate by the clinical phase1. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist […]

By DDW Editor Reece Armstrong A lot has already been said about the US Food and Drug Administration’s (FDA) Modernization Act 2.0 and for good reason. The decision by the Biden administration to end the federal requirement for drugs under development to be tested on animals represents a significant step forward for the life sciences sectors. The legislation […]

It is World Parkinson’s Day (11 April), raising awareness of the fastest growing neurological condition in the world. There is currently no cure, and although there are therapeutics to manage the symptoms, these usually bring side-effects, and so there is still need for new therapeutic options. Here, we take a look at the latest drug […]

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Diana Spencer spoke to Raphael Townshend, PhD, Founder and CEO of Atomic AI, about the advantages of combining two such exciting technologies. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery sector as a tool for […]

Could India become an important centre of drug discovery innovation? Diana Spencer explores the evolution of the Hyderabad life sciences hub. India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines and vaccines. Thanks to a new focus on R&D, […]

Ahead of attending the American Association for Cancer Research (AACR) annual meeting from 14-19 April, 2023 at the Orange County Convention Center in Orlando, Florida, DDW’s Megan Thomas outlines what to expect from the event.   Programme highlights   The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics, to global health, survivorship, prevention […]